Lupus Research Alliance News
LRA Partners with Celgene on Cutting-Edge Research Projects

August 1, 2019 The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, is very pleased to announce a unique new partnership with Celgene Corporation that provides $3,000,000 for bold cutting-edge research projects.  This opportunity will focus on understanding the underlying mechanisms of disease, addressing lupus heterogeneity — how much […] READ MORE

New Trial of Promising Lupus Treatment RSLV-132 Has Finished Enrolling Patients

July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132.  Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […] READ MORE

New Biomarker Research Fast-Tracked

July 30, 2019 Progentec Diagnostics announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) for new biomarker research. The grant has the potential to provide $1.7 million in resources supporting clinical research to see how well lab tests based on biomarkers in the blood […] READ MORE

Fatigue an Issue in Skin Lupus

July 18, 2019 A new study published in The British Journal of Dermatology provides evidence that fatigue is a key symptom, not only of systemic lupus erythematosus (SLE) but also of skin lupus (cutaneous lupus) as well as other autoimmune diseases affecting the skin. Led by an LRA-funded researcher Victoria Werth, MD, the study team […] READ MORE

Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.  Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] READ MORE

More Women with Lupus Having Families

July 12, 2019 In years past, doctors had advised most women with lupus to avoid getting pregnant because of the high risk for both mother and fetus.  A newly published study in Annals of Internal Medicine by Dr. Bella Mehta shows that more women with lupus are having successful pregnancies, while the accompanying editorial by […] READ MORE

LRA-Funded Researchers Present Cutting-Edge Science at FOCIS

July 11, 2019 The annual meeting of the Federation of Clinical Immunology Societies (FOCIS) is the key forum for translational immunology. The Lupus Research Alliance (LRA) is proud to co-sponsor this meeting, which allows researchers and clinicians to share knowledge across disease borders and to chart the path to the next major breakthroughs in disease […] READ MORE

Top Research Needs to Help Kids with Lupus

July 5, 2019 A study published last week in Pediatric Rheumatology identified the top priorities for research into lupus in children. The survey asked pediatric rheumatologists, dermatologists and nephrologists with expertise in lupus to categorize areas of research into high, medium or low priority.  The survey was given to pediatric rheumatologists, dermatologists and nephrologists with […] READ MORE

National Stay Out of the Sun Day

July 3, 2019 Avoiding the sun is something most people with lupus know they just have to live with.  About half of people with lupus experience a “malar” rash that may appear across the cheeks and bridge of the nose in the shape of a butterfly.  Many are sensitive to sunlight (called photosensitivity) meaning that […] READ MORE

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] READ MORE

Skin Molecules Promote Cutaneous Lupus

June 24, 2019 Patients with cutaneous lupus develop rashes because immune cells move into the skin and cause inflammation. With a Target Identification in Lupus (TIL) grant from the Lupus Research Alliance, Dr. Jillian Richmond of the University of Massachusetts Medical School and colleagues found what lures the immune cells into the skin of people […] READ MORE

Learn and connect with our community!